Asset Details
Do you wish to reserve the book?
P13 Seasonal variation in exacerbation risk following severe AECOPD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P13 Seasonal variation in exacerbation risk following severe AECOPD
Do you wish to request the book?
P13 Seasonal variation in exacerbation risk following severe AECOPD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P13 Seasonal variation in exacerbation risk following severe AECOPD
2025
Overview
IntroductionAdmission to hospital with a severe exacerbation of COPD (AECOPD) is associated with an increased risk of further exacerbations, readmission and death. Seasonality can affect exacerbation phenotype (Aung et al, 2024), but it remains unclear how season of onset affects ongoing risk following severe AECOPD.MethodsCOPD-HELP was a single-centre, double-blind, randomised, placebo-controlled trial that recruited 238 participants during hospitalisation for AECOPD and allocated them 1:1 to mepolizumab or placebo for 48 weeks. All participants had an eosinophil count ≥300 cells/µL on at least one occasion in the prior 12 months, were established on inhaled corticosteroids and current or ex-smokers. Full details are published elsewhere. (Flynn et al., 2025)For this analysis, 119 participants on placebo were included. Exacerbation rates were analysed based on an individual’s season of entry into the trial.. Entry into trial occurred within a week of a severe AECOPD for all participants. Exacerbation rates were calculated as the total number of exacerbations per participant, offset by time in trial. A linear regression model was fitted, using season of study enrolment as the primary predictor variable and exacerbation rate in the preceding 12 months as a covariateResultsAdjusted annual exacerbation rates varied significantly by season, with the highest rate in summer (adjusted mean 5.76, 95% CI, 5.33 – 6.19), followed by autumn (4.02, 95% CI, 3.47 – 4.57), spring (3.98, 95% CI, 3.28 – 4.69), and lowest in winter (3.48, 95% CI, 2.92 – 4.04). This represents a relative increase of 65% following an exacerbation in summer compared to winter.Abstract P13 Figure 1[Image Omitted. See PDF.]ConclusionsIn an eosinophilic COPD population, severe exacerbations in summer were associated with a higher rate of exacerbations in the following year than those in any other season. This group may be particularly susceptible to environmental exposures such as increased pollen levels, pollution index or other seasonal allergens. Greater understanding of seasonal dynamics and mechanisms driving recurrent exacerbations could play a role in risk reduction and post exacerbation care and guidance.
Publisher
BMJ Publishing Group LTD
Subject
